Investigational tolebrutinib shows efficacy for non-relapsing secondary progressive multiple sclerosis (SPMS)
Results from a Phase 3 study of treatment with investigational tolebrutinib show a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing… read more.
